These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26348405)

  • 1. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study.
    Matthijsse SM; Hontelez JA; Naber SK; Rozemeijer K; de Kok IM; Bakker R; van Ballegooijen M; van Rosmalen J; de Vlas SJ
    J Infect Dis; 2016 Sep; 214(6):854-61. PubMed ID: 27330051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
    Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
    Regan DG; Philp DJ; Hocking JS; Law MG
    Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
    Bonanni P; Gabutti G; Demarteau N; Boccalini S; La Torre G
    BMC Infect Dis; 2015 Sep; 15():377. PubMed ID: 26381489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
    Ribassin-Majed L; Lounes R; Clémençon S
    PLoS One; 2012; 7(3):e32251. PubMed ID: 22427828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model.
    Matthijsse SM; van Rosmalen J; Hontelez JA; Bakker R; de Kok IM; van Ballegooijen M; de Vlas SJ
    PLoS One; 2015; 10(2):e0116618. PubMed ID: 25642941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
    Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
    Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L; Joura E; Largeron N; Prager B; Uhart M
    BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review.
    Malagón T; Laurie C; Franco EL
    Expert Rev Vaccines; 2018 May; 17(5):395-409. PubMed ID: 29715059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
    Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
    BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study.
    Matthijsse SM; Naber SK; Hontelez JAC; Bakker R; van Ballegooijen M; Lansdorp-Vogelaar I; de Kok IMCM; de Koning HJ; van Rosmalen J; de Vlas SJ
    PLoS One; 2018; 13(9):e0202924. PubMed ID: 30180203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection.
    Korostil IA; Peters GW; Law MG; Regan DG
    Vaccine; 2013 Apr; 31(15):1931-6. PubMed ID: 23434388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
    Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
    PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
    Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
    Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
    Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
    BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of HPV female immunization in Italy: model based predictions.
    Guzzetta G; Faustini L; Panatto D; Gasparini R; Manfredi P
    PLoS One; 2014; 9(3):e91698. PubMed ID: 24618824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.